New Delhi: Ranbaxy Laboratories on Tuesday said its Malaysian unit has started the marketing of anti-hypertensive tablet—Covance—in the local market, which is a generic version of Losartan K.
Ranbaxy Malaysia Sdn Bhd, a subsidiary of the company, has made the day-one-launch of generic Losartan K tablet in Malaysia, Ranbaxy Laboratories said in a statement.
Ranbaxy is the first company to launch a generic version of Losartan K in Malaysia, a company official said. The Indian firm has launched tablets in the strengths of 50 and 100 mg.
The product will be marketed under brand name of Covance and its formulation is bio-equivalent to the innovator, the company said.
“We have launched Covance tablets at an affordable price that will benefit the Malaysian healthcare system and bring substantial cost savings to patients,” Ranbaxy Malaysia managing director Jeyabalan Thangarajah said.
According to the company, the market size of Losartan K tablets in Malaysia is $6.29 million.
“The company (has) obtained necessary approval from the Drug Control Authority in Malaysia to manufacture and market the product locally,” Ranbaxy said.
Ranbaxy’s plant in Malaysia has developed this dosage in collaboration with Indian unit. Covance would be manufactured at the company’s facility in Malaysia, it added.